With $20M, UCSD Spinout Jecure To Press New Attack On NASH
Xconomy
FEBRUARY 15, 2017
Backed by $20 million in Series A funding from Versant Ventures, San Diego-based Jecure aims to develop a new class of drugs to treat an advanced form of fatty liver disease called. Feldstein has been studying the liver for nearly 20 years, and his research now forms the basis of a newly launched company called Jecure Therapeutics.
Let's personalize your content